---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-075013"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2026-07-02T20:30:21+00:00"
generated_at: "2026-07-02T20:32:32.221083+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OS Therapies enters $10M convertible note financing with Leonite Fund; appoints Dr. Craig Eagle to board

## Summary
- Enters securities purchase agreement for up to $10M senior secured convertible note with Leonite Fund I, LP; first tranche of $1.6M expected July 2, 2026.
- Note bears 9% interest, matures 9 months per tranche (max 24 months); conversion price $2.05/share; warrant to buy 1.75M shares at $2.85 through 2031.
- Director Karim Galzahr resigns effective June 1, 2026; Dr. Craig Eagle appointed to fill vacancy, currently serves as Chief Medical Advisor.
- Proceeds to fund clinical development, regulatory activities, and working capital.
- Note secured by substantially all assets (excl. IP); includes negative covenants, anti-dilution adjustments, and 4.99% beneficial ownership limitation.

## SEC filing metadata
- accession: 0001213900-26-075013
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2026-07-02T20:30:21+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390026075013/0001213900-26-075013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390026075013/ea0296868-8k_ostherapies.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-075013
- JSON: https://secwatch.observer/filing/0001213900-26-075013.json
- Plain text: https://secwatch.observer/filing/0001213900-26-075013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.